Stocktoria
Translational Development Acquisition Corp. TDAC
Nasdaq · XNAS · stock · Blank Checks · IPO 2024-12-23
Translational Development Acquisition Corp. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating income | -$944,538 | -$196,358 | -$485,550 |
| Income tax | — | $0 | — |
| Net income | $6.4M | -$71,012 | -$485,550 |
| Operating cash flow | -$608,387 | -$851,446 | -$204 |
| Cash & equivalents | $29,787 | $438,174 | $2,021 |
| Total assets | $181.7M | $175.0M | $2,021 |
| Total liabilities | $6.6M | $6.2M | $509,679 |
| Shareholders' equity | -$6.5M | -$5.6M | -$507,658 |
Source: SEC EDGAR filings · CIK 0001926599 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.